{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:36:38Z","timestamp":1790098598702,"version":"4.0.1"},"reference-count":101,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001674","name":"Fondation Leducq","doi-asserted-by":"publisher","award":["23CVD02"],"award-info":[{"award-number":["23CVD02"]}],"id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL087228"],"award-info":[{"award-number":["HL087228"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL176438"],"award-info":[{"award-number":["HL176438"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL139725"],"award-info":[{"award-number":["HL139725"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL171737"],"award-info":[{"award-number":["HL171737"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jlr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jlr.2026.101050","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:32:46Z","timestamp":1777332766000},"page":"101050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of fenofibrate on angiopoietin-like 3\/4\/8 proteins and apolipoprotein A5"],"prefix":"10.1016","volume":"67","author":[{"given":"Ye","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6540-8179","authenticated-orcid":false,"given":"Sydney","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Q.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene Y.","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0584-4723","authenticated-orcid":false,"given":"Yuewei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4862-6427","authenticated-orcid":false,"given":"Yi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyesoo","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7530-7326","authenticated-orcid":false,"given":"Julia L.","family":"Scheithauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4488-7734","authenticated-orcid":false,"given":"Sander","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0923-0542","authenticated-orcid":false,"given":"Robert J.","family":"Konrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlr.2026.101050_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/ATVBAHA.108.178756","article-title":"Triglyceride-rich lipoproteins and plasma lipid transport","volume":"30","author":"Havel","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2026.101050_bib2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.tem.2020.11.005","article-title":"Lipoprotein lipase and its regulators: an unfolding story","volume":"32","author":"Wu","year":"2021","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.jlr.2026.101050_bib3","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2221888120","article-title":"Inverse effects of APOC2 and ANGPTL4 on the conformational dynamics of lid-anchoring structures in lipoprotein lipase","volume":"120","author":"Kumari","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2026.101050_bib4","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1093\/eurheartj\/ehad261","article-title":"Inverse association between apolipoprotein C-II and cardiovascular mortality: role of lipoprotein lipase activity modulation","volume":"44","author":"Silbernagel","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jlr.2026.101050_bib5","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJM197812282992601","article-title":"Inheritance of apolipoprotein C-II deficiency with hypertriglyceridemia and pancreatitis","volume":"299","author":"Cox","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101050_bib6","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/S0022-2275(20)41340-9","article-title":"Molecular basis of familial chylomicronemia: mutations in the lipoprotein lipase and apolipoprotein C-II genes","volume":"33","author":"Reina","year":"1992","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101050_bib7","doi-asserted-by":"crossref","first-page":"19751","DOI":"10.1073\/pnas.1217552109","article-title":"Atypical angiopoietin-like protein that regulates ANGPTL3","volume":"109","author":"Quagliarini","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2026.101050_bib8","doi-asserted-by":"crossref","first-page":"16109","DOI":"10.1073\/pnas.1315292110","article-title":"Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis","volume":"110","author":"Wang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2026.101050_bib9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.cell.2014.09.027","article-title":"ANGPTL8\/betatrophin does not control pancreatic beta cell expansion","volume":"159","author":"Gusarova","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.jlr.2026.101050_bib10","doi-asserted-by":"crossref","first-page":"11630","DOI":"10.1073\/pnas.1515374112","article-title":"Hepatic ANGPTL3 regulates adipose tissue energy homeostasis","volume":"112","author":"Wang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2026.101050_bib11","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1194\/jlr.M054882","article-title":"Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion","volume":"56","author":"Wang","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101050_bib12","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1194\/jlr.M054890","article-title":"ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys","volume":"56","author":"Gusarova","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101050_bib13","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.150272","article-title":"The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking","volume":"6","author":"Zhang","year":"2016","journal-title":"Open Biol."},{"key":"10.1016\/j.jlr.2026.101050_bib14","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1210\/en.2016-1894","article-title":"ANGPTL8 blockade with a monoclonal antibody promotes triglyceride clearance, energy expenditure, and weight loss in mice","volume":"158","author":"Gusarova","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.jlr.2026.101050_bib15","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1194\/jlr.M075689","article-title":"ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance","volume":"58","author":"Haller","year":"2017","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101050_bib16","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.molmet.2017.06.014","article-title":"ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase","volume":"6","author":"Chi","year":"2017","journal-title":"Mol. Metab."},{"key":"10.1016\/j.jlr.2026.101050_bib17","doi-asserted-by":"crossref","first-page":"E1249","DOI":"10.1073\/pnas.1717420115","article-title":"Increased thermogenesis by a noncanonical pathway in ANGPTL3\/8-deficient mice","volume":"115","author":"Banfi","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2026.101050_bib18","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101050_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138777","article-title":"ANGPTL8 has both endocrine and autocrine effects on substrate utilization","volume":"5","author":"Oldoni","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jlr.2026.101050_bib20","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1194\/jlr.RA120000781","article-title":"Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids","volume":"61","author":"Chen","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101050_bib21","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1210\/clinem\/dgab120","article-title":"Genetic and metabolic determinants of plasma levels of ANGPTL8","volume":"106","author":"Oldoni","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jlr.2026.101050_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2021.101140","article-title":"An updated ANGPTL3-4-8 model as a mechanism of triglyceride partitioning between fat and oxidative tissues","volume":"85","author":"Zhang","year":"2022","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101050_bib23","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2420721122","article-title":"ANGPTL3\/8 is an atypical unfoldase that regulates intravascular lipolysis by catalyzing unfolding of lipoprotein lipase","volume":"122","author":"Kumari","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2026.101050_bib24","article-title":"The angiopoietin-like protein ANGPTL4 catalyzes unfolding of the hydrolase domain in lipoprotein lipase and the endothelial membrane protein GPIHBP1 counteracts this unfolding","volume":"5","author":"Mysling","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.jlr.2026.101050_bib25","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172600","article-title":"Hypertriglyceridemia in Apoa5\u2013\/\u2013 mice results from reduced amounts of lipoprotein lipase in the capillary lumen","volume":"133","author":"Yang","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jlr.2026.101050_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100198","article-title":"An anti-ANGPTL3\/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif","volume":"63","author":"Balasubramaniam","year":"2022","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101050_bib27","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/s41591-025-03830-4","article-title":"Targeting the angiopoietin-like protein 3\/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial","volume":"31","author":"Gaudet","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.jlr.2026.101050_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1126\/science.1064852","article-title":"An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing","volume":"294","author":"Pennacchio","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jlr.2026.101050_bib29","doi-asserted-by":"crossref","first-page":"44512","DOI":"10.1074\/jbc.M106888200","article-title":"Apolipoprotein AV: a novel apolipoprotein associated with an early phase of liver regeneration","volume":"276","author":"van der Vliet","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101050_bib30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1373\/clinchem.2004.040824","article-title":"The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins","volume":"51","author":"O'Brien","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jlr.2026.101050_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100068","article-title":"APOA5 lowers triglyceride levels via suppression of ANGPTL3\/8-mediated LPL inhibition","volume":"62","author":"Chen","year":"2021","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101050_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100578","article-title":"APOA5 deficiency causes hypertriglyceridemia by reducing amounts of lipoprotein lipase in capillaries","volume":"65","author":"Yang","year":"2024","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101050_bib33","article-title":"Carboxyl-terminal sequences in APOA5 are important for suppressing ANGPTL3\/8 activity","volume":"121","author":"Chen","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2026.101050_bib34","article-title":"A neutralizing APOA5 monoclonal antibody reduces amounts of lipoprotein lipase in capillaries and triggers hypertriglyceridemia","volume":"123","author":"Yang","year":"2026","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2026.101050_bib35","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1172\/JCI24471","article-title":"APOA5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment","volume":"115","author":"Mar\u00e7ais","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jlr.2026.101050_bib36","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/01.ATV.0000153087.36428.dd","article-title":"Inherited apolipoprotein AV deficiency in severe hypertriglyceridemia","volume":"25","author":"Priore Oliva","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2026.101050_bib37","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2796.2007.01912.x","article-title":"Hypertriglyceridemia and low plasma HDL in a patient with apolipoprotein AV deficiency due to a novel mutation in the APOA5 gene","volume":"263","author":"Priore Oliva","year":"2008","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.jlr.2026.101050_bib38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.atherosclerosis.2009.04.021","article-title":"Modulation of phenotypic expression of APOA5 Q97X and L242P mutations","volume":"207","author":"Charri\u00e8re","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jlr.2026.101050_bib39","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1471-2350-13-106","article-title":"APOA5 Q97X mutation identified through homozygosity mapping causes severe hypertriglyceridemia in a Chilean consanguineous family","volume":"13","author":"Dussaillant","year":"2012","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.jlr.2026.101050_bib40","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1194\/jlr.M031195","article-title":"Structural and functional analysis of APOA5 mutations identified in patients with severe hypertriglyceridemia","volume":"54","author":"Mendoza-Barbera","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101050_bib41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2013.12.009","article-title":"Homozygosity for a partial deletion of apolipoprotein AV signal peptide results in intracellular missorting of the protein and chylomicronemia in a breast-fed infant","volume":"233","author":"Albers","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jlr.2026.101050_bib42","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jacl.2016.07.009","article-title":"Frameshift mutation in the APOA5 gene causing hypertriglyceridemia in a Pakistani family: management and considerations for cardiovascular risk","volume":"10","author":"Th\u00e9riault","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.jlr.2026.101050_bib43","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/MOL.0000000000000916","article-title":"Genetic variation in apolipoprotein A-V in hypertriglyceridemia","volume":"35","author":"Perera","year":"2024","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.jlr.2026.101050_bib44","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2214081120","article-title":"Angiopoietin-like protein 4\/8 complex-mediated plasmin generation leads to cleavage of the complex and restoration of LPL activity","volume":"120","author":"Zhen","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2026.101050_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2023.100441","article-title":"Decoding the role of angiopoietin-like protein 4\/8 complex-mediated plasmin generation in the regulation of LPL activity","volume":"64","author":"Chen","year":"2023","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101050_bib46","doi-asserted-by":"crossref","first-page":"13213","DOI":"10.1074\/jbc.M900553200","article-title":"Genetic variation in ANGPTL4 provides insights into protein processing and function","volume":"284","author":"Yin","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101050_bib47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","article-title":"Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies","volume":"3","author":"Hokanson","year":"1996","journal-title":"J. Cardiovasc. Risk"},{"key":"10.1016\/j.jlr.2026.101050_bib48","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jlr.2026.101050_bib49","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019343","article-title":"Coronary heart disease risk associated with primary isolated hypertriglyceridemia; a population-based study","volume":"10","author":"Saadatagah","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.jlr.2026.101050_bib50","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature13917","article-title":"Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction","volume":"518","author":"Do","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jlr.2026.101050_bib51","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2017.0972","article-title":"Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease","volume":"317","author":"Khera","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jlr.2026.101050_bib52","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/ng1984","article-title":"Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL","volume":"39","author":"Romeo","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jlr.2026.101050_bib53","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.metabol.2008.06.016","article-title":"Variation in ANGPTL4 and risk of coronary heart disease: the atherosclerosis risk in communities study","volume":"57","author":"Folsom","year":"2008","journal-title":"Metabolism"},{"key":"10.1016\/j.jlr.2026.101050_bib54","first-page":"70","article-title":"Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans","volume":"119","author":"Romeo","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jlr.2026.101050_bib55","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101050_bib56","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","article-title":"Inactivating variants in ANGPTL4 and risk of coronary artery disease","volume":"374","author":"Dewey","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101050_bib57","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jlr.2026.101050_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009501","article-title":"ANGPTL8 protein-truncating variant associated with lower serum triglycerides and risk of coronary disease","volume":"17","author":"Helkkula","year":"2021","journal-title":"Plos Genet."},{"key":"10.1016\/j.jlr.2026.101050_bib59","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1161\/ATVBAHA.124.321308","article-title":"Circulating ANGPTL3\/8 concentrations are associated with an atherogenic lipoprotein profile and increased CHD risk in Swedish population\u2013based studies","volume":"45","author":"Leander","year":"2025","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2026.101050_bib60","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1161\/CIRCULATIONAHA.124.069272","article-title":"Associations of circulating ANGPTL3, C-terminal domain-containing ANGPTL4, and ANGPTL3\/8 and ANGPTL4\/8 complexes with LPL activity, diabetes, inflammation, and cardiovascular mortality","volume":"151","author":"Silbernagel","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jlr.2026.101050_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120485","article-title":"Associations of ANGPTL proteins and complexes with progression of coronary artery calcification and coronary events","volume":"409","author":"Silbernagel","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jlr.2026.101050_bib62","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101050_bib63","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group","volume":"341","author":"Rubins","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101050_bib64","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jlr.2026.101050_bib65","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jlr.2026.101050_bib66","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jlr.2026.101050_bib67","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(10)60758-1","article-title":"Fibrates in CVD: a step towards personalised medicine","volume":"375","author":"Staels","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jlr.2026.101050_bib68","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101050_bib69","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101050_bib70","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMe2213208","article-title":"The fibrates story\u2014a tepid end to a PROMINENT drug","volume":"387","author":"Virani","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101050_bib71","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1056\/NEJMc2216470","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"388","author":"Van Regemorter","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101050_bib72","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12933-024-02305-z","article-title":"Lessons from PROMINENT and prospects for pemafibrate","volume":"23","author":"Fruchart","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.jlr.2026.101050_bib73","doi-asserted-by":"crossref","first-page":"27307","DOI":"10.1074\/jbc.272.43.27307","article-title":"Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice","volume":"272","author":"Peters","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101050_bib74","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0026-0495(77)90053-1","article-title":"Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia","volume":"26","author":"Nikkil\u00e4","year":"1977","journal-title":"Metabolism"},{"key":"10.1016\/j.jlr.2026.101050_bib75","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/0021-9150(96)05854-6","article-title":"Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and Apo C-III genes by activating the nuclear receptor PPAR","volume":"124","author":"Auwerx","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jlr.2026.101050_bib76","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1172\/JCI117717","article-title":"Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates","volume":"95","author":"Staels","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jlr.2026.101050_bib77","doi-asserted-by":"crossref","first-page":"28488","DOI":"10.1074\/jbc.M004029200","article-title":"Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene","volume":"275","author":"Kersten","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101050_bib78","doi-asserted-by":"crossref","first-page":"34411","DOI":"10.1074\/jbc.M403058200","article-title":"The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF\/PGAR\/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment","volume":"279","author":"Mandard","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101050_bib79","article-title":"Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials","volume":"8","author":"Sahebkar","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jlr.2026.101050_bib80","doi-asserted-by":"crossref","first-page":"31521","DOI":"10.1074\/jbc.M103306200","article-title":"Differential gene regulation in human versus rodent hepatocytes by Peroxisome Proliferator-Activated Receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expresson","volume":"276","author":"Lawrence","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101050_bib81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006796","article-title":"Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human","volume":"4","author":"Rakhshandehroo","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jlr.2026.101050_bib82","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1186\/s12864-018-4834-3","article-title":"The whole transcriptome effects of the PPAR\u03b1 agonist fenofibrate on livers of hepatocyte humanized mice","volume":"19","author":"de la Rosa Rodriguez","year":"2018","journal-title":"BMC Genomics"},{"key":"10.1016\/j.jlr.2026.101050_bib83","doi-asserted-by":"crossref","first-page":"25468","DOI":"10.1074\/jbc.M301302200","article-title":"The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element","volume":"278","author":"Prieur","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101050_bib84","doi-asserted-by":"crossref","first-page":"17982","DOI":"10.1074\/jbc.M212191200","article-title":"Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators","volume":"278","author":"Vu-Dac","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101050_bib85","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.bbalip.2009.03.015","article-title":"Differential regulation of the human versus the mouse apolipoprotein AV gene by PPARalpha. Implications for the study of pharmaceutical modifiers of hypertriglyceridemia in mice","volume":"1791","author":"Prieur","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jlr.2026.101050_bib86","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.numecd.2010.12.010","article-title":"Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects","volume":"22","author":"Bragt","year":"2012","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.jlr.2026.101050_bib87","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.202100192","article-title":"Comparative analysis of the effects of fish oil and fenofibrate on plasma metabolomic profiles in overweight and obese individuals","volume":"66","author":"Michielsen","year":"2022","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.jlr.2026.101050_bib88","first-page":"1073","article-title":"Cholesteryl ester transfer protein activity correlates inversely with apolipoprotein A5 levels","volume":"19","author":"Wen","year":"2025","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.jlr.2026.101050_bib89","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jlr.2026.101050_bib90","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1194\/jlr.C500010-JLR200","article-title":"Administration of a PPAR-alpha agonist increases serum apolipoprotein AV levels and the apolipoprotein AV\/apolipoprotein CIII ratio","volume":"46","author":"Schultze","year":"2005","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101050_bib91","doi-asserted-by":"crossref","first-page":"13470","DOI":"10.1074\/jbc.270.22.13470","article-title":"Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III","volume":"270","author":"Hertz","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101050_bib92","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0021-9150(99)00337-8","article-title":"Postprandial concentrations and distribution of Apo C-III in type 2 diabetic patients. Effect of bezafibrate treatment","volume":"149","author":"Attia","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jlr.2026.101050_bib93","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/07853890310011969","article-title":"Contribution of Apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients","volume":"35","author":"Lemieux","year":"2003","journal-title":"Ann. Med."},{"key":"10.1016\/j.jlr.2026.101050_bib94","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1074\/jbc.M008809200","article-title":"Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil","volume":"276","author":"Dallongeville","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101050_bib95","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1152\/physiolgenomics.00100.2011","article-title":"Comparative transcriptomic and metabolomic analysis of fenofibrate and fish oil treatments in mice","volume":"43","author":"Lu","year":"2011","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.jlr.2026.101050_bib96","doi-asserted-by":"crossref","first-page":"302","DOI":"10.5551\/jat.65941","article-title":"Pemafibrate increases circulating angiopoietin-like proteins 3 and 4 without promoting pro-atherogenic changes in LDL and HDL subspecies: a post-hoc analysis of the PRESTIGE study","volume":"33","author":"Hirano","year":"2025","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.jlr.2026.101050_bib97","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1152\/physiolgenomics.00115.2011","article-title":"Detailed transcriptomics analysis of the effect of dietary fatty acids on gene expression in the heart","volume":"44","author":"Georgiadi","year":"2012","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.jlr.2026.101050_bib98","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1152\/physiolgenomics.00198.2006","article-title":"Genome-wide analysis of PPARalpha activation in murine small intestine","volume":"30","author":"B\u00fcnger","year":"2007","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.jlr.2026.101050_bib99","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1194\/jlr.M500005-JLR200","article-title":"Differential regulation and properties of angiopoietin-like proteins 3 and 4","volume":"46","author":"Ge","year":"2005","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101050_bib100","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: from orphan receptors to drug discovery","volume":"43","author":"Willson","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jlr.2026.101050_bib101","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1158\/0008-5472.CAN-04-0322","article-title":"Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha","volume":"64","author":"Cheung","year":"2004","journal-title":"Cancer Res."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227526000763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227526000763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:14:28Z","timestamp":1783127668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227526000763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0022227526000763"],"URL":"https:\/\/doi.org\/10.1016\/j.jlr.2026.101050","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of fenofibrate on angiopoietin-like 3\/4\/8 proteins and apolipoprotein A5","name":"articletitle","label":"Article Title"},{"value":"Journal of Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlr.2026.101050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"101050"}}